Telix Pharmaceuticals (TLX) to Release Quarterly Earnings on Thursday

Key Points

• Telix Pharmaceuticals is expected to report H1 2026 results before the market opens on August 20. Analysts forecast earnings of $0.0434 per share and revenue of approximately $479.6 million.
• TLX shares opened at $11.97, near their 52-week high of $12.60, while several institutional investors recently increased their holdings or initiated new positions.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $20.40, although ratings include a recent downgrade from RBC and a “sell” rating from Weiss Ratings.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) will likely be announcing its H1 2026 results before the market opens on Thursday, August 20th. Analysts expect the company to announce earnings of $0.0434 per share and revenue of $479.6290 million for the quarter. Individuals may visit the the company's upcoming H1 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 19, 2026 at 7:00 PM ET.

Telix Pharmaceuticals Trading Down 0.2%

Shares of TLX opened at $11.97 on Thursday. Telix Pharmaceuticals has a 52-week low of $6.28 and a 52-week high of $12.60. The business's fifty day moving average is $10.61 and its 200-day moving average is $9.46. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several hedge funds have recently modified their holdings of TLX. Portland Investment Counsel Inc. increased its holdings in Telix Pharmaceuticals by 108.0% in the 4th quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company's stock worth $2,063,000 after purchasing an additional 138,200 shares in the last quarter. Lazard Asset Management LLC boosted its stake in shares of Telix Pharmaceuticals by 118.6% during the fourth quarter. Lazard Asset Management LLC now owns 250,517 shares of the company's stock valued at $1,876,000 after purchasing an additional 135,893 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Telix Pharmaceuticals during the third quarter valued at about $1,883,000. Russell Investments Group Ltd. bought a new stake in shares of Telix Pharmaceuticals during the second quarter worth about $975,000. Finally, Private Advisor Group LLC grew its holdings in shares of Telix Pharmaceuticals by 67.3% during the third quarter. Private Advisor Group LLC now owns 42,112 shares of the company's stock worth $403,000 after purchasing an additional 16,945 shares during the last quarter.

Analysts Set New Price Targets

TLX has been the topic of several research analyst reports. Citigroup reduced their price objective on Telix Pharmaceuticals from $22.50 to $22.00 and set a "buy" rating on the stock in a research note on Tuesday, July 7th. Weiss Ratings reissued a "sell (d)" rating on shares of Telix Pharmaceuticals in a research note on Friday, July 17th. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a report on Tuesday, July 7th. Wedbush restated an "outperform" rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Monday, July 6th. Finally, Royal Bank Of Canada downgraded shares of Telix Pharmaceuticals from an "outperform" rating to a "sector perform" rating in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $20.40.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source